Autoantibodies to type I interferons in patients with systemic mastocytosis

• Published in: The journal of allergy and clinical immunology. Global Vol. 3; no. 3; p. 100273
• Main Authors: Cao, Vivian, Lee, Serena J., Bai, Yun, Holland, Steven M., Rosen, Lindsey B., Metcalfe, Dean D., Komarow, Hirsh D.
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.08.2024; Elsevier
• Subjects: Autoantibodies; autoimmune; Brief Report; COVID-19; cytokines; inflammatory; mast cell; mastocytosis; type I interferons; COVID-19; Autoantibodies; FI; autoimmune; mastocytosis; inflammatory; mast cell; cytokines; MCA; SM; type I interferons
• ISSN: 2772-8293; 2772-8293
• DOI: 10.1016/j.jacig.2024.100273

Autoantibodies to type I interferons have been identified in association with a variety of inflammatory and autoimmune diseases. Type I interferons have demonstrated inhibitory effects on mast cell proliferation and degranulation. Systemic mastocytosis (SM) is a disease characterized by increased mast cell burden and mediator release. Whether autoantibodies to type I interferon are present in the sera of patients with SM, and if so, whether they correlate with characteristics of disease, is unknown. The purpose of this study was to determine whether autoantibodies to type I interferons are observed in the sera of patients with SM, and if so, whether they correlate with biomarkers of disease severity. We analyzed sera from 89 patients with SM for concentrations of autoantibodies to type I interferon by using a multiplex particle-based assay and signal neutralization capacity by using a STAT1 activity assay and then compared these measurements with those in a database of information on 1284 healthy controls. Our cohort was predominantly female (57.3%), with a median age of 56 years. Of the cohort members, 13 produced autoantibodies to IFN-β, 3 to IFN-ω, and 0 to IFN-α. None of the 13 sera demonstrated signal neutralization. Neither autoantibody concentration nor signaling inhibition measurements correlated with tryptase concentrations or D816V allele burden. Although a small subpopulation of patients with SM have autoantibodies to type I interferons, there was no correlation between autoantibody production and signaling inhibition. These data are consistent with the conclusion that autoantibodies to type I interferon do not play a significant role in the pathogenesis or severity of SM.